argininosuccinate

argininosuccinate

/ar·gi·ni·no·suc·cin·ate/ (ahr″jĭ-ne″no-suk´sĭ-nāt) the anionic form of argininosuccinic acid.
References in periodicals archive ?
MPM and NSCLC patients with tumor cells deficient in the enzyme argininosuccinate synthetase (ASS1) enrolled in the study received standard dose cisplatin + pemetrexed, and increasing doses of ADI-PEG 20 treatment.
Primary causes of hyperammonemia include congenital enzymopathies in the urea cycle, such as deficiencies of ornithine transcarbamoylase and argininosuccinate lyase.
Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase.
Additional galU genes were found adjacent to the gene argH encoding argininosuccinate lyase in the sequenced genomes from isolates a275, 29031, H-ASH/87, and H-ZANE/83, and although the genes were conserved, they were not identical to the galU genes found within the cps locus.
After demonstrating hyperammonaemia, a specific diagnosis can be made by analysing plasma amino acids, including citrulline and argininosuccinate, and by measuring orotate in urine.
Increased citrulline indicates a deficiency in either argininosuccinate synthase or argininosuccinate lyase (1).
Molecular analysis of human argininosuccinate lyase: mutant characterization and alternative splicing of the coding region.
On the other hand, in uricotelic species, this reaction is the only path of endogenous synthesis of Arg, through the catalytic action of argininosuccinate lyase and argininosuccinate synthetase on citrulline.
ASL: Cytosol 1:218,750 AR Argininosuccinate lyase (argininosuccinic aciduria) 5.
Having completed a successful randomized phase 2 trial in argininosuccinate synthetase -deficient MPM patients with ADI-PEG 20 as monotherapy, Polaris is currently conducting a phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin, the approved first-line treatment for MPM, for the treatment of MPM and non-squamous non-small cell lung carcinoma.